Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 View HTML
0001558370-22-006381.pdf
0001558370-22-006381.rtf
0001558370-22-006381.xls
DEFA14A

Additional proxy soliciting materials - definitive

 View HTML
0001558370-22-006383.pdf
0001558370-22-006383.rtf
0001558370-22-006383.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001415889-22-004061.pdf
0001415889-22-004061.rtf
0001415889-22-004061.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-044050.pdf
0001104659-22-044050.rtf
0001104659-22-044050.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-003957.pdf
0001415889-22-003957.rtf
0001415889-22-003957.xls
3/A

An amendment to a 3 filing. Non-EDGAR filing

 View HTML
0001415889-22-003505.pdf
0001415889-22-003505.rtf
0001415889-22-003505.xls
4/A

Amendment to a previously filed 4

 View HTML
0001415889-22-003506.pdf
0001415889-22-003506.rtf
0001415889-22-003506.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-003280.pdf
0001415889-22-003280.rtf
0001415889-22-003280.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-003186.pdf
0001415889-22-003186.rtf
0001415889-22-003186.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002923.pdf
0001415889-22-002923.rtf
0001415889-22-002923.xls